Free China Movement

Evidence · Human Rights · Democratic Future

Take Action

English 简体中文 繁體中文 Français Deutsch Español

🔎

Centralized Drug Procurement and Medical Insurance: Sharply Lower Prices, Near-Universal Coverage, New Quality and Sustainability Tests

Integrity labels: OFFICIAL POLICY / OFFICIAL STATISTICS / EXTERNAL PERSPECTIVE / CURRENT FCM GOVERNING ALTERNATIVE

Policy question

Since December 2018, China’s National Healthcare Security Administration (NHSA) has run volume-based centralized drug procurement (带量采购): pooling national hospital demand and awarding contracts to the lowest qualified bidder. Separately, the basic medical insurance system now covers about 95% of the population. The governance issue is twofold: whether extreme price competition preserves drug quality and supply reliability, and whether the medical insurance fund can stay solvent as an aging population drives costs upward.

What the policy gets right

The procurement model attacks a genuine problem — inflated drug prices — with a mechanism that deserves fair credit. Pooling volume and awarding on price has delivered steep, documented savings: across the first ten national rounds, 435 drug types were covered with average price cuts around 50%, according to the NHSA; the December 2024 tenth round alone (62 drugs, 385 winning products from 234 firms) averaged reductions above 70%, with some generics falling to cents per tablet. Winning drugs must pass quality-consistency evaluations. The program has also shown learning: after industry complaints that rock-bottom bids threatened quality, the 2025 Government Work Report put procurement quality supervision on the agenda for the first time, and rules for the 11th round (registration opened September 2025) require bids at or above production cost, hospital demand reporting by brand, and public justification for below-anchor bids — an explicit “anti-involution” turn.

On insurance, near-universal enrollment is a real achievement. The NHSA’s 2025 statistical bulletin reports 1.33 billion basic medical insurance participants — coverage held at 95% — with fund income of 3.59 trillion yuan against expenditure of 3.01 trillion yuan, leaving a pooled-fund current surplus of 526 billion yuan. Reimbursement rates remain around 80% for urban employees and 70% for residents’ hospitalization. An August 2024 State Council guidance on long-term enrollment mechanisms tackled real threats — adverse selection, the strain of a large floating population, and rising personal contributions — with reward and waiting-period mechanisms.

What the evidence shows

The quality question is unresolved, not settled. Caixin’s reporting on the tenth round documented industry alarm: hundreds of companies bidding, some winning prices near production cost, and physicians and patients raising concerns about efficacy of ultra-cheap generics and about the loss of choice as hospitals commit to contracted volumes. NHSA officials counter that all selected drugs pass consistency evaluations and that quality monitoring is being strengthened. These are competing stakeholder claims, not a controlled quality study; no public dataset directly links procurement batches to treatment outcomes, which is itself a transparency gap.

On sustainability, the fund currently runs a surplus, but the pressures are structural: an aging population, a hospitalization rate of 21.86% versus an OECD average of about 14% (figures reported in NHSA-linked policy analyses), and out-of-pocket exposure that still deters care for the elderly. Enrollment is also fragile at the margin — the 2024 guidance exists precisely because healthy young people are opting out, and because the system’s large floating population strains enrollment stability. These are official and analytical data points, not a fund insolvency forecast; they indicate risk direction, not a verdict.

Historical FCM record

No contemporaneous FCM position on the centralized drug procurement program or medical insurance policy has yet been verified. The following recommendations are a current governance proposal and are not backdated.

FCM governing alternative

A Third Republic should keep the savings while making quality verifiable and the fund transparently sustainable. Concretely: (1) Publish a drug-level quality surveillance dataset — batch failure rates, adverse-event reports, and hospital-level substitution complaints for every procured drug — updated quarterly. (2) Give physicians a formal clinical override: the right to prescribe a non-contracted equivalent when documented in the patient record, without hospital penalty. (3) Require the NHSA to publish a 10-year actuarial projection of the medical insurance fund under published demographic and cost assumptions, updated every two years, with the assumptions open to independent audit. (4) Cap out-of-pocket spending for catastrophic illness as a share of household income, published as an enforceable entitlement. (5) Make procurement bid evaluations public in redacted form — scores, quality weights, and the rationale for each award — so price-only competition can be seen and challenged.

How to measure success

  • Average price reduction per procurement round vs. batch-level quality failure rates.
  • Published physician clinical-override rates and hospital drug-supply interruption incidents.
  • Medical insurance fund income, expenditure, and cumulative balance, published quarterly with actuarial projections.
  • Catastrophic out-of-pocket spending incidence among the lowest income quintile.
  • Resident and employee enrollment rates by age group, tracking adverse selection.
  • Independent patient satisfaction with drug efficacy and choice.

Sources

Related Governance sections: Historical Chinese Policy & Democratic Responses; Policy Scorecard & Outcomes; Third Republic Governance Blueprints; Policy Evolution & Social Influence.

Languages: English · 简体中文 · 繁體中文 · Français · Deutsch · Español